AMPK‐mediated prevention of vascular dysfunction with metformin: Experimental and population‐based evidence
Open Access
- 10 June 2026
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (17) , 5389-5406
Abstract
Background and Purpose: Metformin is increasingly recognised for its vasculoprotective effects, primarily through activation of AMP‐activated protein kinase (AMPK). We combined population‐based genetic epidemiology, with an ex vivo vascular model, to investigate the beneficial vascular effects of AMPK activation by metformin. Experimental Approach: We used genetically proxied AMPK activation (GP‐AMPK), based on 20 genome‐wide significant single‐nucleotide polymorphisms (SNPs), to assess associations with pulse wave velocity (PWV) and carotid intima‐media thickness (cIMT). A two‐sample Mendelian randomisation (MR) was performed to test the effect of GP‐AMPK on a panel of inflammatory markers. We also developed a porcine coronary artery model of endothelial dysfunction to test the restorative effects of metformin on vascular function and related molecular signalling pathways. Key Results: Higher GP‐AMPK activation was associated with lower PWV, but not cIMT, in our epidemiological analysis (mean age 64.3 years, 43.8% female). Ex vivo, metformin restored endothelial relaxation in Angiotensin (Ang) II–treated vessels via endothelium‐dependent hyperpolarisation (EDH) mechanisms, an effect abolished by AMPK inhibition. Western blotting confirmed the activation of AMPK (alpha 1 subunit) with metformin treatment. Inhibitor studies demonstrated a shift from NO‐mediated to EDH‐mediated relaxation with metformin. Molecular analyses showed reduced Ang II–induced expression of matrix remodelling (MMP1, MMP2) and senescence (P21) markers, as well as suppression of pro‐inflammatory cytokines (Il‐1β, Il‐6, TNF‐α), consistent with MR results. Conclusion and Implications: Metformin restored endothelial function and reduced vascular stiffness through an AMPK–EDH axis, highlighting a novel, potential therapeutic mechanism for early vascular dysfunction independent of glycaemic effects.Keywords
This publication has 71 references indexed in Scilit:
- Metformin: An Old Drug with New Tricks—Promising Role in Vascular Aging and CardioprotectionDrugs & Aging, 2025
- The Rotterdam Study. Design update and major findings between 2020 and 2024European Journal of Epidemiology, 2024
- Update on the Use of Pulse Wave Velocity to Measure Age-Related Vascular ChangesCurrent Hypertension Reports, 2023
- Protective effects of metformin in the pro-inflammatory cytokine induced intestinal organoids injury modelBiochemical and Biophysical Research Communications, 2023
- Mitochondrial Inhibition: a Treatment Strategy in Cancer?Current Oncology Reports, 2021
- Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation studyDiabetologia, 2020
- Objectives, design and main findings until 2020 from the Rotterdam StudyEuropean Journal of Epidemiology, 2020
- Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: Relevance in age-associated vascular dysfunctionBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2018
- The mechanisms of action of metforminDiabetologia, 2017
- Methods of data collection and definitions of cardiac outcomes in the Rotterdam StudyEuropean Journal of Epidemiology, 2012